ClinicalTrials.gg
CompletedNCT02880852Updated Mar 27, 2020Results posted

Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus

A Phase 1 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
30th of 36
20 · median 81
Started
2017
the only one that year
Phase 1
7 of 36
none open now
Registered
23rd of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 30th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 1, and was the 23rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

In China, Belimumab (GSK1550188) will be developed for a dosing regimen of once-monthly intravenous (IV) infusion for the treatment of SLE. This open-label, single dose study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of belimumab in Chinese SLE subjects. A total of approximately 20 subjects will be enrolled to receive IV infusion of 10 milligrams per kilogram (mg/kg) GSK1550188 on Day 0 for the treatment of SLE. Subjects will be followed for 84 days after the administration of drug.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
  • Belimumab
  • Pharmacodynamics
  • safety tolerability
  • Pharmacokinetics
  • Chinese subjects
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who give consent to this study participation and sign form.
  • Subjects at least 18 years of age inclusive at screening visit.
  • SLE Classification: Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria, with 4 or more of the 11 ACR criteria present, serially or simultaneously during any interval or observation.
  • SLE Treatment: Be on either no SLE medication or a stable SLE treatment regimen of any medication (alone or in combination) for a period of at least 2 months prior to Day 0; (prednisone or prednisone equivalent, up to 40 mg/day); or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), mizoribine, calcineurin inhibitors (example [e.g.], tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide; anti-malarials (e.g., hydroxychloroquine, chloroquine, quinacrine) and non-steroidal anti-inflammatory drugs (NSAIDs).
  • The subjects with positive test for anti-nuclear antibody (ANA) or anti-double stranded deoxyribonucleic acid (DNA) serum antibody.
  • Males and females: A female subject is eligible to enter the study if she is: not pregnant or nursing; of non- (i.e., women who had a hysterectomy, are which is defined as 1 year without menses, have both ovaries surgically removed or have current documented tubal ligation); of childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhoea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at screening, and agree to one of the following: complete abstinence from penile-vaginal intercourse, when this is the female's preferred and usual lifestyle, from 2 weeks prior to administration of the 1st dose of product (IP) until study complete; or consistent and correct use of one of the following acceptable methods of for 1 month prior to the start of the IP and for 16 weeks after the last dose of IP: any intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1 percent (%) per year; oral contraceptives; double barrier method with vaginal spermicidal agent: condom and an occlusive cap (cervical cap/vault or diaphragm) with a vaginal spermicidal agent (foam/gel/film/cream/suppository); implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; injectable progesterone; percutaneous contraceptive patch; male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subject.
  • Based on single or averaged (QTc) interval values of triplicate ECGs obtained over a brief recording period: [QTc corrected by Bazett's (QTcB) or QTc corrected by Fridericia's (QTcF) formula] \<450 milliseconds (msec); or QTcB or QTcF \<480 msec in subjects with bundle branch block.

Exclusion criteria

Exclusion Criteria:

  • B-cell Therapy: Have received treatment with any B cell targeted therapy (e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], BLyS-receptor fusion protein [BR3], Transmembrane activator and calcium-modulator and cytophilin ligand interactor [TACI] Fc, or belimumab) at any time.
  • The subject has received a biologic or non-investigational agent within 12 months prior to Day 0.
  • Received IV immunoglobulin (Ig), plasmapheresis, hemodialysis, intravenous cyclophosphamide, or high dose prednisone and its equivalents (>60 mg/day) within 6 months prior to Day 0.
  • The subject has received a non-biologic investigational agent within 2 months prior to Day 0.
  • The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational agent.
  • The subject has severe lupus kidney disease (defined by proteinuria >6 grams [g]/24 hours) within 6 months prior to the Screening visit.
  • History of renal transplant.
  • Active central nervous system (CNS) lupus [including seizures, psychosis, organic brain syndrome, cerebrovascular accident (CVA), motor neuropathy, vasculitis] requiring medical intervention within 6 months prior to Screening visit.
  • Infections: Have required management of acute or chronic infections, as follows: currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria); hospitalization for treatment of infection within 2 months prior to Day 0; use of parenteral (IV or intramuscular [IM]) antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) within 2 months prior to Day 0.
  • The subject has hypogammaglobulinemia or immunoglobulin A (IgA) deficiency (IgA level \<10 mg/deciliter [dL]).
  • Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
  • Uncontrolled other diseases: History or clinical evidence of active significant acute or chronic diseases (i.e., cardiovascular, pulmonary, untreated hypertension, anemia, gastrointestinal, hepatic, renal, neurological, cancer, or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk.
  • Have a planned surgical procedure, or a history of any other medical disease, or laboratory abnormalities, or conditions which would make the subject (in the opinion of the Investigator) unsuitable for the study.
  • The subject has an abnormality on 12-lead at screening which is in the opinion of the investigator.
  • Have evidence of current drug or alcohol abuse or dependence.
  • and ALT >=2x (ULN); ALP and >1.5xULN (isolated bilirubin >1.5ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Have a historically positive (HIV) test or test positive at screening for HIV.
  • History of or positive test at screening visit for any of surface antigen (HBsAg), anti- Hepatitis B core antibody (HBcAb) or anti- virus antibodies (HCVAb). If only anti-HBcAb result is positive, hepatitis B virus (HBV)-(DNA) test will be performed. If HBV-DNA results in negative, the patient is eligible.
  • Laboratory Abnormalities: Have a Grade 3 or greater laboratory abnormality based on the protocol toxicity scale except for the following that are allowed:
  • Stable Grade 3 (PT) secondary to warfarin treatment.
  • Stable Grade 3/4 proteinuria (=\<6 g/24 hour equivalent by spot urine protein to creatinine ratio allowed).
  • Stable Grade 3 hypoalbuminemia due to lupus nephritis, and not related to liver disease or malnutrition.
  • Stable Grade 3 neutropenia or stable Grade 3 white blood cell count.
  • Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months or who, in the investigator's opinion, pose a significant suicide risk.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Belimumab 10 mg/kg

    In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.

    Drug: Belimumab

Interventions

  • Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Belimumab

    Blood samples were collected at the indicated timepoints to calculate Cmax of belimumab.

    Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose

  2. Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0 to t]) and Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0 to Inf]) of Belimumab

    Blood samples were collected at the indicated timepoints to calculate AUC (0 to t) and AUC (0 to inf) of belimumab.

    Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose

  3. Terminal Phase Half-life (t1/2) of Belimumab

    Blood samples were collected at the indicated time points to calculate t1/2 of belimumab.

    Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose

  4. Terminal Phase Rate Constant (Lambda z) of Belimumab

    Blood samples were collected at the indicated time points to calculate lambda z of belimumab.

    Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose

  5. Systemic Clearance (CL) of Belimumab

    Blood samples were collected at the indicated time points to calculate CL of belimumab.

    Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose

  6. Volume of Distribution (Vz) of Belimumab

    Blood samples were collected at the indicated time points to calculate Vz of belimumab.

    Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose

  7. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant, or associated with liver injury and impaired liver function.

    Time frame: Up to Day 84

Secondary outcomes

  1. Change From Baseline to Day 84 in Vital Signs- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital signs included SBP and DBP. SBP and DBP were measured with the participant in the sitting position. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  2. Change From Baseline to Day 84 in Vital Sign- Pulse Rate

    Vital signs included pulse rate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  3. Change From Baseline to Day 84 in Vital Sign- Temperature

    Vital signs included temperature. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  4. Number of Participants With Abnormal-clinically Significant 12-lead Electrocardiogram (ECG) Findings

    ECG parameters included heart rate, PR interval, QRS interval, QT interval and corrected QT (QTc) interval. Number of participants with abnormal-clinically significant 12-lead ECG findings are presented.

    Time frame: Up to Day 84

  5. Change From Baseline to Day 84 in Clinical Chemistry Parameters- Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase

    Clinical chemistry parameters included ALT, ALP, AST, GGT and lactate dehydrogenase. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  6. Change From Baseline to Day 84 in Clinical Chemistry Parameters- Albumin and Protein

    Clinical chemistry parameters included albumin and protein. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  7. Change From Baseline to Day 84 in Clinical Chemistry Parameters- Bilirubin, Creatinine, Direct Bilirubin, Indirect Bilirubin and Urate

    Clinical chemistry parameters included bilirubin, creatinine, direct bilirubin, indirect bilirubin and urate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  8. Change From Baseline to Day 84 in Clinical Chemistry Parameters- Calcium, Calcium Corrected, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium, Sodium, Urea and Glucose

    Clinical chemistry parameters included calcium, calcium corrected, carbon dioxide, chloride, magnesium, phosphate, potassium, sodium, urea and glucose. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  9. Change From Baseline to Day 84 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Hematology parameters included basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  10. Change From Baseline to Day 84 in Hematology Parameter- Erythrocytes

    Hematology parameter included erythrocytes. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  11. Change From Baseline to Day 84 in Hematology Parameter- Hematocrit

    Hematology parameter included hematocrit. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  12. Change From Baseline to Day 84 in Hematology Parameter- Hemoglobin

    Hematology parameter included hemoglobin. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  13. Number of Participants With Positive Urinalysis Dipstick Results

    Urinalysis was done by the dipstick method to detect the presence of protein, glucose, ketones and occult blood in urine. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine occult blood, urine protein and urine ketones can be read as negative, Trace, 1+, 2+, 3+ and 4+, indicating proportional concentrations in the urine sample; results for urinalysis parameter of urine glucose can be read as negative, Trace, 1+ or 1/4 gram per Liter (g/L), 2+ or 1/2 g/L, 3+ or 1 g/L and 4+ indicating proportional concentrations in the urine sample. \*a indicates two participants did not take the urinalysis test at Day 14 on scheduled date but took an unscheduled sample at the next visit (Day 21) and \*b indicates one participant did not take the urinalysis test at Day 28 on scheduled date but took an unscheduled sample at the next visit (Day 42). Only those participants with positive results have been presented.

    Time frame: Day 0 (24 hours), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84

  14. Percent Change From Baseline to Day 84 in B Cell Subsets (Cluster of Differentiation [CD]19 and CD 20+) for Pharmacodynamic Assessment

    Immunoglobulin B cell subsets included CD19 and CD 20+. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\]. Pharmacodynamic population comprised of participants who received the study medication and for whom pharmacodynamic data was available.

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  15. Percent Change From Baseline to Day 84 in B Cell Subsets (CD20+/27+ Memory and CD20+/27-naïve) for the Pharmacodynamic Assessment

    Immunoglobulin B cell subset included CD20+/27+ memory and CD20+/27-naïve. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].

    Time frame: Baseline (pre-dose on Day 0) to Day 84

  16. Percent Change From Baseline to Day 84 in Immunoglobulins B Cell Subset (Normalized [Norm] CD19+/27BRIGHT[Br]/38Br SLE Subset, Norm CD20+/138+Plasmacytoid, Norm CD20+/69+Activated and Norm CD20-/CD138+Plasma Cell) for Pharmacodynamic Assessment

    Immunoglobulin B cell subset inlcuded Norm CD19+/27Br/38Br SLE subset, Norm CD20+/138+plasmacytoid, Norm CD20+/69+activated and Norm CD20-/CD138+plasma cell. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].

    Time frame: Baseline (pre-dose on Day 0) to Day 84

07

Results

Posted Nov 9, 2018

Participant flow

A total of 20 participants with Systemic Lupus Erythematosus (SLE) were enrolled. The study was conducted at 2 centers in China from 23-Jan-2017 to 08-Sep-2017.

Participant flow — Overall Study
MilestoneBelimumab 10 mg/kg
Started20
Completed20
Not completed0

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Belimumab

Blood samples were collected at the indicated timepoints to calculate Cmax of belimumab.

Time frame:
Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Observed Concentration (Cmax) of Belimumab
Micrograms per milliliterBelimumab 10 mg/kg
Maximum Observed Concentration (Cmax) of Belimumab221.3532 ± 12.8405
PrimaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0 to t]) and Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0 to Inf]) of Belimumab

Blood samples were collected at the indicated timepoints to calculate AUC (0 to t) and AUC (0 to inf) of belimumab.

Time frame:
Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Reported as:
Geometric mean · Day*micrograms/milliliter
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0 to t]) and Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0 to Inf]) of Belimumab
Day*micrograms/milliliterBelimumab 10 mg/kg
AUC(0 to t)2395.3030 ± 23.2924
AUC(0 to inf)2461.8013 ± 24.7125
PrimaryTerminal Phase Half-life (t1/2) of Belimumab

Blood samples were collected at the indicated time points to calculate t1/2 of belimumab.

Time frame:
Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Reported as:
Geometric mean · Days
Terminal Phase Half-life (t1/2) of Belimumab
DaysBelimumab 10 mg/kg
Terminal Phase Half-life (t1/2) of Belimumab14.6283 ± 35.4339
PrimaryTerminal Phase Rate Constant (Lambda z) of Belimumab

Blood samples were collected at the indicated time points to calculate lambda z of belimumab.

Time frame:
Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Reported as:
Geometric mean · 1/day
Terminal Phase Rate Constant (Lambda z) of Belimumab
1/dayBelimumab 10 mg/kg
Terminal Phase Rate Constant (Lambda z) of Belimumab0.0474 ± 35.4339
PrimarySystemic Clearance (CL) of Belimumab

Blood samples were collected at the indicated time points to calculate CL of belimumab.

Time frame:
Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Reported as:
Geometric mean · (Milliliters/day)/kilogram
Systemic Clearance (CL) of Belimumab
(Milliliters/day)/kilogramBelimumab 10 mg/kg
Systemic Clearance (CL) of Belimumab4.0621 ± 24.7125
PrimaryVolume of Distribution (Vz) of Belimumab

Blood samples were collected at the indicated time points to calculate Vz of belimumab.

Time frame:
Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Reported as:
Geometric mean · Milliliters/kilogram
Volume of Distribution (Vz) of Belimumab
Milliliters/kilogramBelimumab 10 mg/kg
Volume of Distribution (Vz) of Belimumab85.7265 ± 21.6704
PrimaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant, or associated with liver injury and impaired liver function.

Time frame:
Up to Day 84
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsBelimumab 10 mg/kg
AE12
SAE1
SecondaryChange From Baseline to Day 84 in Vital Signs- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital signs included SBP and DBP. SBP and DBP were measured with the participant in the sitting position. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Millimeters of mercury
Change From Baseline to Day 84 in Vital Signs- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryBelimumab 10 mg/kg
DBP: Day 0 (5 minutes post-dose)-0.5 ± 6.35
DBP: Day 0 (1 hour post-dose)-1.5 ± 12.51
DBP: Day 0 (6 hours post-dose)-2.1 ± 8.57
DBP: Day 0 (24 hours post-dose)-0.1 ± 7.95
DBP: Day 12.2 ± 8.37
DBP: Day 71.1 ± 7.91
DBP: Day 140.5 ± 8.65
DBP: Day 210.1 ± 6.91
DBP: Day 280.2 ± 8.86
DBP: Day 42-3.2 ± 7.99
DBP: Day 56-0.8 ± 8.85
DBP: Day 84-0.6 ± 11.06
SBP: Day 0 (5 minutes post-dose)0.8 ± 9.92
SBP: Day 0 (1 hour post-dose)-2.5 ± 11.44
SBP: Day 0 (6 hours post-dose)-4.5 ± 12.15
SBP: Day 0 (24 hours post-dose)-3.7 ± 11.76
SBP: Day 1-2.4 ± 10.92
SBP: Day 70.7 ± 10.65
SBP: Day 14-1.0 ± 12.09
SBP: Day 21-4.4 ± 12.05
SBP: Day 28-1.5 ± 14.01
SBP: Day 42-7.4 ± 9.26
SBP: Day 56-4.0 ± 11.14
SBP: Day 84-7.4 ± 14.91
SecondaryChange From Baseline to Day 84 in Vital Sign- Pulse Rate

Vital signs included pulse rate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Beats per minute
Change From Baseline to Day 84 in Vital Sign- Pulse Rate
Beats per minuteBelimumab 10 mg/kg
Day 0 (5 minutes post-dose)-1.2 ± 11.13
Day 0 (1 hour post-dose)-1.6 ± 8.43
Day 0 (6 hours post-dose)2.6 ± 12.14
Day 0 (24 hours post-dose)2.3 ± 11.08
Day 15.7 ± 11.09
Day 74.7 ± 11.82
Day 146.9 ± 10.55
Day 215.0 ± 8.90
Day 287.6 ± 10.02
Day 428.3 ± 12.06
Day 564.1 ± 10.80
Day 843.2 ± 14.21
SecondaryChange From Baseline to Day 84 in Vital Sign- Temperature

Vital signs included temperature. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Celsius
Change From Baseline to Day 84 in Vital Sign- Temperature
CelsiusBelimumab 10 mg/kg
Day 0 (5 minutes post-dose)0.21 ± 0.485
Day 0 (1 hour post-dose)0.17 ± 0.473
Day 0 (6 hours post-dose)0.20 ± 0.552
Day 0 (24 hours post-dose)0.40 ± 0.617
Day 10.24 ± 0.486
Day 70.40 ± 0.793
Day 140.40 ± 0.504
Day 210.41 ± 0.454
Day 280.37 ± 0.457
Day 420.53 ± 0.595
Day 560.52 ± 0.473
Day 840.38 ± 0.434
SecondaryNumber of Participants With Abnormal-clinically Significant 12-lead Electrocardiogram (ECG) Findings

ECG parameters included heart rate, PR interval, QRS interval, QT interval and corrected QT (QTc) interval. Number of participants with abnormal-clinically significant 12-lead ECG findings are presented.

Time frame:
Up to Day 84
Reported as:
Count of participants · Participants
Number of Participants With Abnormal-clinically Significant 12-lead Electrocardiogram (ECG) Findings
ParticipantsBelimumab 10 mg/kg
Number of Participants With Abnormal-clinically Significant 12-lead Electrocardiogram (ECG) Findings0
SecondaryChange From Baseline to Day 84 in Clinical Chemistry Parameters- Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase

Clinical chemistry parameters included ALT, ALP, AST, GGT and lactate dehydrogenase. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · International units per Liter (IU/L)
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase
International units per Liter (IU/L)Belimumab 10 mg/kg
ALT: Day 0 (24 hours)-1.6 ± 3.46
ALT: Day 14-1.3 ± 11.93
ALT: Day 28-3.2 ± 12.34
ALT: Day 56-5.0 ± 12.18
ALT: Day 84-5.5 ± 11.84
ALP: Day 0 (24 hours)-3.9 ± 3.56
ALP: Day 14-5.6 ± 10.72
ALP: Day 28-3.4 ± 8.80
ALP: Day 56-7.2 ± 9.26
ALP: Day 84-7.3 ± 11.80
AST: Day 0 (24 hours)-1.9 ± 2.48
AST: Day 14-1.8 ± 8.58
AST: Day 28-2.6 ± 8.46
AST: Day 56-2.8 ± 6.15
AST: Day 84-3.6 ± 6.86
GGT: Day 0 (24 hours)-1.5 ± 2.33
GGT: Day 14-0.5 ± 7.34
GGT: Day 280.5 ± 7.22
GGT: Day 56-4.1 ± 6.08
GGT: Day 84-3.3 ± 8.44
Lactate dehydrogenase: Day 0 (24 hours)-8.1 ± 10.56
Lactate dehydrogenase: Day 14-3.2 ± 18.88
Lactate dehydrogenase: Day 28-1.4 ± 22.30
Lactate dehydrogenase: Day 561.3 ± 24.30
Lactate dehydrogenase: Day 841.5 ± 20.68
SecondaryChange From Baseline to Day 84 in Clinical Chemistry Parameters- Albumin and Protein

Clinical chemistry parameters included albumin and protein. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Albumin and Protein
Grams per liter (g/L)Belimumab 10 mg/kg
Albumin: Day 0 (24 hours)-1.4 ± 1.88
Albumin: Day 14-1.1 ± 3.08
Albumin: Day 28-0.6 ± 2.68
Albumin: Day 56-0.5 ± 3.14
Albumin: Day 84-0.6 ± 3.10
Protein: Day 0 (24 hours)-3.8 ± 2.67
Protein: Day 14-3.2 ± 5.12
Protein: Day 28-3.3 ± 4.47
Protein: Day 56-3.8 ± 5.41
Protein: Day 84-3.8 ± 4.23
SecondaryChange From Baseline to Day 84 in Clinical Chemistry Parameters- Bilirubin, Creatinine, Direct Bilirubin, Indirect Bilirubin and Urate

Clinical chemistry parameters included bilirubin, creatinine, direct bilirubin, indirect bilirubin and urate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Micromoles per Liter (µmol/L)
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Bilirubin, Creatinine, Direct Bilirubin, Indirect Bilirubin and Urate
Micromoles per Liter (µmol/L)Belimumab 10 mg/kg
Bilirubin: Day 0 (24 hours)-2.8 ± 3.07
Bilirubin: Day 14-2.4 ± 4.48
Bilirubin: Day 28-3.4 ± 4.55
Bilirubin: Day 56-3.2 ± 5.17
Bilirubin: Day 84-2.1 ± 4.83
Creatinine: Day 0 (24 hours)-0.18 ± 4.479
Creatinine: Day 14-0.80 ± 5.502
Creatinine: Day 28-0.43 ± 6.698
Creatinine: Day 56-0.25 ± 5.962
Creatinine: Day 84-0.18 ± 6.062
Direct bilirubin: Day 0 (24 hours)-0.4 ± 1.05
Direct bilirubin: Day 140.1 ± 1.37
Direct bilirubin: Day 28-0.6 ± 1.14
Direct bilirubin: Day 56-0.6 ± 1.47
Direct bilirubin: Day 84-0.2 ± 1.28
Indirect bilirubin: Day 0 (24 hours)-2.4 ± 2.87
Indirect bilirubin: Day 14-2.5 ± 4.10
Indirect bilirubin: Day 28-2.8 ± 4.12
Indirect bilirubin: Day 56-2.6 ± 4.26
Indirect bilirubin: Day 84-1.9 ± 4.79
Urate: Day 0 (24 hours)-14.5 ± 21.88
Urate: Day 14-10.5 ± 34.41
Urate: Day 28-13.5 ± 47.49
Urate: Day 56-2.5 ± 49.93
Urate: Day 84-7.5 ± 50.67
SecondaryChange From Baseline to Day 84 in Clinical Chemistry Parameters- Calcium, Calcium Corrected, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium, Sodium, Urea and Glucose

Clinical chemistry parameters included calcium, calcium corrected, carbon dioxide, chloride, magnesium, phosphate, potassium, sodium, urea and glucose. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Millimoles per Liter (mmol/L)
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Calcium, Calcium Corrected, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium, Sodium, Urea and Glucose
Millimoles per Liter (mmol/L)Belimumab 10 mg/kg
Calcium: Day 0 (24 hours)-0.040 ± 0.0599
Calcium: Day 14-0.020 ± 0.1049
Calcium: Day 280.004 ± 0.0848
Calcium: Day 56-0.020 ± 0.1054
Calcium: Day 84-0.027 ± 0.0909
Calcium Corrected: Day 0 (24 hours)-0.010 ± 0.0466
Calcium Corrected: Day 140.003 ± 0.0663
Calcium Corrected: Day 280.017 ± 0.0578
Calcium Corrected: Day 56-0.007 ± 0.0694
Calcium Corrected: Day 84-0.016 ± 0.0501
Carbon dioxide: Day 0 (24 hours)-0.3 ± 1.86
Carbon dioxide: Day 14-0.2 ± 2.32
Carbon dioxide: Day 280.1 ± 2.09
Carbon dioxide: Day 56-0.1 ± 2.33
Carbon dioxide: Day 84-0.2 ± 1.64
Chloride: Day 0 (24 hours)1.3 ± 2.12
Chloride: Day 140.3 ± 2.05
Chloride: Day 280.4 ± 1.53
Chloride: Day 561.3 ± 1.63
Chloride: Day 841.2 ± 1.74
Magnesium: Day 0 (24 hours)-0.044 ± 0.0564
Magnesium: Day 14-0.046 ± 0.0623
Magnesium: Day 28-0.049 ± 0.0709
Magnesium: Day 56-0.029 ± 0.0750
Magnesium: Day 84-0.034 ± 0.0751
Phosphate: Day 0 (24 hours)-0.085 ± 0.1299
Phosphate: Day 14-0.132 ± 0.2104
Phosphate: Day 28-0.135 ± 0.2201
Phosphate: Day 56-0.140 ± 0.2037
Phosphate: Day 84-0.152 ± 0.1509
Potassium: Day 0 (24 hours)-0.10 ± 0.333
Potassium: Day 14-0.04 ± 0.355
Potassium: Day 28-0.11 ± 0.335
Potassium: Day 56-0.13 ± 0.370
Potassium: Day 84-0.29 ± 0.356
Sodium: Day 0 (24 hours)0.1 ± 2.24
Sodium: Day 140.3 ± 1.59
Sodium: Day 280.1 ± 1.28
Sodium: Day 560.8 ± 1.68
Sodium: Day 840.8 ± 1.67
Urea: Day 0 (24 hours)0.20 ± 0.733
Urea: Day 140.38 ± 1.122
Urea: Day 280.10 ± 1.382
Urea: Day 56-0.13 ± 0.793
Urea: Day 84-0.20 ± 1.152
Glucose: Day 0 (24 hours)0.98 ± 3.248
Glucose: Day 141.66 ± 2.094
Glucose: Day 280.33 ± 2.230
Glucose: Day 560.19 ± 2.093
Glucose: Day 840.57 ± 2.749
SecondaryChange From Baseline to Day 84 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

Hematology parameters included basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · 10^9 cells/Liter
Change From Baseline to Day 84 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
10^9 cells/LiterBelimumab 10 mg/kg
Basophils: Day 0 (24 hours)-0.006 ± 0.0110
Basophils: Day 14-0.011 ± 0.0176
Basophils: Day 28-0.013 ± 0.0186
Basophils: Day 56-0.008 ± 0.0162
Basophils: Day 84-0.005 ± 0.0115
Eosinophils: Day 0 (24 hours)-0.019 ± 0.0506
Eosinophils: Day 14-0.024 ± 0.0564
Eosinophils: Day 28-0.006 ± 0.0535
Eosinophils: Day 56-0.022 ± 0.0595
Eosinophils: Day 84-0.028 ± 0.0670
Leukocytes: Day 0 (24 hours)0.29 ± 0.899
Leukocytes: Day 140.09 ± 1.403
Leukocytes: Day 281.00 ± 1.589
Leukocytes: Day 560.54 ± 1.337
Leukocytes: Day 84-0.04 ± 1.754
Lymphocytes: Day 0 (24 hours)-0.068 ± 0.5214
Lymphocytes: Day 14-0.180 ± 0.6718
Lymphocytes: Day 28-0.364 ± 0.6746
Lymphocytes: Day 56-0.287 ± 0.5812
Lymphocytes: Day 84-0.257 ± 0.5697
Monocytes: Day 0 (24 hours)0.005 ± 0.1300
Monocytes: Day 14-0.025 ± 0.1575
Monocytes: Day 28-0.077 ± 0.2568
Monocytes: Day 56-0.076 ± 0.1574
Monocytes: Day 84-0.059 ± 0.1878
Neutrophils: Day 0 (24 hours)0.389 ± 0.9085
Neutrophils: Day 140.332 ± 1.8713
Neutrophils: Day 281.464 ± 1.9750
Neutrophils: Day 560.932 ± 1.3943
Neutrophils: Day 840.305 ± 1.7297
Platelets: Day 0 (24 hours)-6.3 ± 12.68
Platelets: Day 142.1 ± 26.11
Platelets: Day 2810.0 ± 30.14
Platelets: Day 561.0 ± 20.84
Platelets: Day 84-4.1 ± 29.04
SecondaryChange From Baseline to Day 84 in Hematology Parameter- Erythrocytes

Hematology parameter included erythrocytes. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · 10^12 cells/Liter
Change From Baseline to Day 84 in Hematology Parameter- Erythrocytes
10^12 cells/LiterBelimumab 10 mg/kg
Day 0 (24 hours)-0.12 ± 0.158
Day 14-0.19 ± 0.246
Day 28-0.13 ± 0.205
Day 56-0.16 ± 0.239
Day 84-0.18 ± 0.282
SecondaryChange From Baseline to Day 84 in Hematology Parameter- Hematocrit

Hematology parameter included hematocrit. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline to Day 84 in Hematology Parameter- Hematocrit
Proportion of red blood cells in bloodBelimumab 10 mg/kg
Day 0 (24 hours)-0.0112 ± 0.0170
Day 14-0.0176 ± 0.0272
Day 280.0006 ± 0.0310
Day 56-0.0060 ± 0.0226
Day 84-0.0126 ± 0.0313
SecondaryChange From Baseline to Day 84 in Hematology Parameter- Hemoglobin

Hematology parameter included hemoglobin. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Grams per Liter (g/L)
Change From Baseline to Day 84 in Hematology Parameter- Hemoglobin
Grams per Liter (g/L)Belimumab 10 mg/kg
Day 0 (24 hours)-3.7 ± 4.83
Day 14-5.0 ± 7.14
Day 28-4.0 ± 5.55
Day 56-5.0 ± 8.04
Day 84-5.7 ± 10.11
SecondaryNumber of Participants With Positive Urinalysis Dipstick Results

Urinalysis was done by the dipstick method to detect the presence of protein, glucose, ketones and occult blood in urine. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine occult blood, urine protein and urine ketones can be read as negative, Trace, 1+, 2+, 3+ and 4+, indicating proportional concentrations in the urine sample; results for urinalysis parameter of urine glucose can be read as negative, Trace, 1+ or 1/4 gram per Liter (g/L), 2+ or 1/2 g/L, 3+ or 1 g/L and 4+ indicating proportional concentrations in the urine sample. \*a indicates two participants did not take the urinalysis test at Day 14 on scheduled date but took an unscheduled sample at the next visit (Day 21) and \*b indicates one participant did not take the urinalysis test at Day 28 on scheduled date but took an unscheduled sample at the next visit (Day 42). Only those participants with positive results have been presented.

Time frame:
Day 0 (24 hours), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84
Reported as:
Count of participants · Participants
Number of Participants With Positive Urinalysis Dipstick Results
ParticipantsBelimumab 10 mg/kg
Glucose: Day 14, 1+ or 1/4 g/L1
Glucose: Day 14, 2+ or 1/2 g/L1
Glucose: Day 14, Trace1
Glucose: Day 28, 1+ or 1/4 g/L1
Glucose: Day 56, 1+ or 1/4 g/L1
Occult Blood: Day 0 (24 hours), Trace5
Occult Blood: Day 0 (24 hours), 1+1
Occult Blood: Day 0 (24 hours), 3+1
Occult Blood: Day 14, Trace4
Occult Blood: Day 14, 1+2
Occult Blood: Day 14, 2+1
Occult Blood: Day 21*a, Trace1
Occult Blood: Day 28, Trace6
Occult Blood: Day 28, 2+2
Occult Blood: Day 56, Trace5
Occult Blood: Day 56, 1+2
Occult Blood: Day 56, 2+2
Occult Blood: Day 84, Trace1
Occult Blood: Day 84, 1+3
Occult Blood: Day 84, 2+1
Protein: Day 0 (24 hours), 2+1
Protein: Day 14, Trace3
Protein: Day 14, 1+1
Protein: Day 28, 2+1
Protein: Day 42*b, Trace1
Protein: Day 56, Trace2
Protein: Day 84, Trace3
Protein: Day 84, 2+1
SecondaryPercent Change From Baseline to Day 84 in B Cell Subsets (Cluster of Differentiation [CD]19 and CD 20+) for Pharmacodynamic Assessment

Immunoglobulin B cell subsets included CD19 and CD 20+. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\]. Pharmacodynamic population comprised of participants who received the study medication and for whom pharmacodynamic data was available.

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Percent change
Percent Change From Baseline to Day 84 in B Cell Subsets (Cluster of Differentiation [CD]19 and CD 20+) for Pharmacodynamic Assessment
Percent changeBelimumab 10 mg/kg
CD19: Day 14, n=2026.6444 ± 78.2275
CD19: Day 28, n=20-4.1141 ± 49.0574
CD19: Day 42, n=19-12.6852 ± 46.6312
CD19: Day 56, n=20-20.4908 ± 44.2536
CD19: Day 84, n=20-27.0912 ± 49.5965
CD20+: Day 14, n=2035.3407 ± 100.7209
CD20+: Day 28, n=200.3444 ± 54.1435
CD20+: Day 42, n=19-8.6327 ± 52.1804
CD20+: Day 56, n=20-20.6313 ± 42.8535
CD20+: Day 84, n=20-23.7421 ± 62.8031
SecondaryPercent Change From Baseline to Day 84 in B Cell Subsets (CD20+/27+ Memory and CD20+/27-naïve) for the Pharmacodynamic Assessment

Immunoglobulin B cell subset included CD20+/27+ memory and CD20+/27-naïve. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Percent change
Percent Change From Baseline to Day 84 in B Cell Subsets (CD20+/27+ Memory and CD20+/27-naïve) for the Pharmacodynamic Assessment
Percent changeBelimumab 10 mg/kg
CD20+/27+ memory: Day 14, n=20186.4701 ± 199.5187
CD20+/27+ memory: Day 28, n=20118.1433 ± 135.2351
CD20+/27+ memory: Day 42, n=1991.2965 ± 125.1803
CD20+/27+ memory: Day 56, n=20135.8139 ± 167.0084
CD20+/27+ memory: Day 84, n=2070.6332 ± 108.1058
CD20+/27-naïve: Day 14, n=204.0530 ± 61.8752
CD20+/27-naïve: Day 28, n=20-15.9190 ± 48.8363
CD20+/27-naïve: Day 42, n=19-17.0090 ± 61.5514
CD20+/27-naïve: Day 56, n=20-40.2078 ± 37.1774
CD20+/27-naïve: Day 84, n=20-42.6608 ± 43.8690
SecondaryPercent Change From Baseline to Day 84 in Immunoglobulins B Cell Subset (Normalized [Norm] CD19+/27BRIGHT[Br]/38Br SLE Subset, Norm CD20+/138+Plasmacytoid, Norm CD20+/69+Activated and Norm CD20-/CD138+Plasma Cell) for Pharmacodynamic Assessment

Immunoglobulin B cell subset inlcuded Norm CD19+/27Br/38Br SLE subset, Norm CD20+/138+plasmacytoid, Norm CD20+/69+activated and Norm CD20-/CD138+plasma cell. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].

Time frame:
Baseline (pre-dose on Day 0) to Day 84
Reported as:
Mean · Percent change
Percent Change From Baseline to Day 84 in Immunoglobulins B Cell Subset (Normalized [Norm] CD19+/27BRIGHT[Br]/38Br SLE Subset, Norm CD20+/138+Plasmacytoid, Norm CD20+/69+Activated and Norm CD20-/CD138+Plasma Cell) for Pharmacodynamic Assessment
Percent changeBelimumab 10 mg/kg
Norm CD19+/27Br/38Br SLE subset: Day 14, n=205.3271 ± 85.7472
Norm CD19+/27Br/38Br SLE subset: Day 28, n=20-4.4623 ± 91.3321
Norm CD19+/27Br/38Br SLE subset: Day 42, n=1917.2492 ± 132.2146
Norm CD19+/27Br/38Br SLE subset: Day 56, n=2048.1481 ± 148.1877
Norm CD19+/27Br/38Br SLE subset: Day 84, n=2024.9838 ± 118.1567
Norm CD20+/138+plasmacytoid: Day 14, n=19200.6464 ± 702.0072
Norm CD20+/138+plasmacytoid: Day 28, n=19255.8559 ± 1010.9303
Norm CD20+/138+plasmacytoid: Day 42, n=182.7891 ± 145.0411
Norm CD20+/138+plasmacytoid: Day 56, n=1920.1061 ± 220.7714
Norm CD20+/138+plasmacytoid: Day 84, n=19-44.0743 ± 65.0501
Norm CD20+/69+activated: Day 14, n=19-0.9711 ± 196.9956
Norm CD20+/69+activated: Day 28, n=19106.5032 ± 379.9580
Norm CD20+/69+activated: Day 42, n=189.8018 ± 138.7995
Norm CD20+/69+activated: Day 56, n=1915.6984 ± 132.7055
Norm CD20+/69+activated: Day 84, n=19-18.3523 ± 120.1047
Norm CD20-/CD138+plasma cells: Day 14, n=2024.3489 ± 151.0876
Norm CD20-/CD138+plasma cells: Day 28, n=2021.4906 ± 180.2169
Norm CD20-/CD138+plasma cells: Day 42, n=19-6.6055 ± 129.1377
Norm CD20-/CD138+plasma cells: Day 56, n=203.0692 ± 175.5913
Norm CD20-/CD138+plasma cells: Day 84, n=20-51.0462 ± 38.0848

Adverse events

Collected over Up to Day 84. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 10 mg/kg0/20 (0%)1/20 (5%)11/20 (55%)
Most frequent serious events
Most frequent serious events
EventBelimumab 10 mg/kg
NeutropeniaBlood and lymphatic system disorders1/20
Upper respiratory tract infectionInfections and infestations1/20
Most frequent other events
Showing 10 of 13
Most frequent other events
EventBelimumab 10 mg/kg
Upper respiratory tract infectionInfections and infestations4/20
HyperglycaemiaMetabolism and nutrition disorders2/20
GingivitisInfections and infestations1/20
PharyngitisInfections and infestations1/20
AnaemiaBlood and lymphatic system disorders1/20
HypokalaemiaMetabolism and nutrition disorders1/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/20
Productive coughRespiratory, thoracic and mediastinal disorders1/20
Bone infarctionMusculoskeletal and connective tissue disorders1/20
OsteoarthritisMusculoskeletal and connective tissue disorders1/20

Baseline characteristics

Safety Population which comprised of all the participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Belimumab 10 mg/kg
Mean37.4 ± 14.07
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 10 mg/kg
Female16
Male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab 10 mg/kg
Asian - East Asian Heritage20
08

Study locations

2 sites
  • GSK Investigational Site
    Shanghai, China
  • GSK Investigational Site
    Suzhou, 215004, China
09

References and documents

Publications

  • Zhang J, Wan W, Miao L, Wu J, Dong J, Shen Y, Xiong C, Li C, Xue Y, Cao G, Ma P. Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. Rheumatol Ther. 2020 Mar;7(1):191-200. doi: 10.1007/s40744-020-00193-9. Epub 2020 Jan 17. PubMed 31953740 ↗
  • Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. doi: 10.1007/s40268-021-00369-w. Epub 2021 Nov 6. PubMed 34741731 ↗
  • Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9. PubMed 34628605 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2017, 7 months.

Results were first posted in Nov 2018, 1 year 2 months after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 7 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2016
First posted
Aug 26, 2016
StartActual
Jan 23, 2017
Primary completionActual
Sep 8, 2017
CompletionActual
Sep 8, 2017
Results first posted
Nov 9, 2018
Last update
Mar 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02880852
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 26, 2016
Start date
Jan 23, 2017
Primary completion
Sep 8, 2017
Completion
Sep 8, 2017
Results posted
Nov 9, 2018
Last update
Mar 27, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion